Web Exclusive

Quizartinib Significantly Improves Survival Over Chemotherapy in Patients with Relapsed/Refractory AML and FLT3-ITD Mutation
Web Exclusives
These results make quizartinib the first FLT3 inhibitor to demonstrate such improvement over chemotherapy in this patient population.
Breaking News: Sellas Announces Promising Data on NeuVax in Combination with Herceptin in HER2 1+/2+ Breast Cancer
Web Exclusives
NeuVax + Herceptin may provide a clinically meaningful benefit to breast cancer patients with low to intermediate HER2-expression.
With Emerging Oncology Therapies and Rising Patient Responsibilities, Financial Navigation Will Have a Greater Role in Cancer Care
Web Exclusives
Emerging pharmacologic therapies used for the treatment of oncology are being developed and approved at an accelerated rate.
What’s New in Navigation: New Metrics and Physician Collaboration
Tricia Strusowski, RN, MS
Web Exclusives
AONN+ Navigation Metrics can be incorporated into partnerships between oncology patient navigators and physician practices.
Loading More Articles

Results 1 - 4 of 4

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
    Country
     
    Continue

  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code
    Go Back
SUBSCRIBE

Contact Us | Editorial Board

© 2009-2018 DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512